Furthermore, targeted therapy has recently shown promising potential in TETs, especially in thymic carcinoma, where KIT inhibitors, VEGFR/multikinase inhibitors (such as sunitinib), and mTOR inhibitors (such as everolimus) have been introduced as second-line treatments for cases refractory to first-line chemotherapy [8,9]. Here, MTOR is linked to thymic carcinoma.